VKTX250509C26000
- 2.40
- +0.74+44.58%
Viking Therapeutics Newsroom
Why Viking Therapeutics Stock Was Victorious This Week
Viking Therapeutics Call Volume Above Normal and Directionally Bullish
Where Will Viking Therapeutics Be in 3 Years?
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Viking Therapeutics Options Spot-On: On April 29th, 53,329 Contracts Were Traded, With 176.65K Open Interest
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Cantor Fitzgerald Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $104
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $75
New Analyst Forecast: $VKTX Given 'Overweight' Rating
Viking Therapeutics Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $104
Leadership in Action: Max Roix Promoted to Advisor for Viking M&A's Florida Division
Why Viking Therapeutics Stock Popped Today
Truist Securities Reiterates Buy on Viking Therapeutics, Lowers Price Target to $75
Viking Therapeutics Participates in a Conference Call With Maxim Group
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $71 to $118
Viking Therapeutics | 10-Q: Q1 2025 Earnings Report
Viking Therapeutics Insiders Sold US$21m Of Shares Suggesting Hesitancy
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025
Viking Therapeutics Price Target Cut to $102.00/Share From $105.00 by Morgan Stanley